Asymmetrically Disubstituted Pyrenebutyrate Complexes of Pt(IV) as Cisplatin Prodrugs with Improved Anticancer Activity
Molecules · 03.07.2026 · 31 (13) · 2336
DOI: 10.3390/molecules31132336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 03.07.2026. Verfasst von Rositsa Mihaylova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Street, 1000 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Prodrugs, Antineoplastic Agents, Cisplatin, Pyrenes. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Fund of Bulgaria.
Abstract (Originalsprache)
Among the non-classical platinum complexes, Pt(IV) prodrugs are most promising as versatile scaffolds for structural modification and fine tuning of their activation-by-reduction mechanism of action and the resulting anticancer activity. Herein, four new asymmetrically disubstituted pyrenebutyrate complexes of Pt(IV) (2–5) were synthesized and thoroughly studied. In this series, the second axial ligand was derived from dicarboxylic acids of different length—4 and 5 C-atoms, or replacement of the C-atom in the middle with either O- or S-atom. The structural effects on reduction kinetics, lipophilicity and cellular internalization of the complexes were monitored by NMR, HPLC, fluorescence and ICP-MS measurements. Their cytotoxicity was tested on a panel of cancer cell lines and mechanistic insights were obtained from proteome analysis and microscope imaging. The data indicate that all complexes, especially complex 3, represent a promising class of Pt(IV) prodrugs, exhibiting significantly higher cytotoxic activity than cisplatin in all tested models, including a cisplatin-resistant line. This was explained with a stronger and more integrated apoptotic response than cisplatin: pronounced Bax upregulation (3.6-fold), maximal cleaved caspase-3 (4-fold), activation of both intrinsic and extrinsic pathways, and effective p53 Ser15/Ser46 phosphorylation. The consistent rank order of potency (3 > 4 > 5 ≈ 2 ≫ cisplatin) suggests that subtle ligand modifications can substantially enhance efficacy, possibly by improving cellular uptake or altering DNA binding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Medical University-Sofia, 2 Dunav Street, 1000 Sofia, Bulgaria.
- Faculty of Chemistry and Pharmacy, Sofia University, 1, J. Bourchier blvd., 1164 Sofia, Bulgaria.
- Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. G. Bonchev Str. Bl. 9, 1113 Sofia, Bulgaria.
ORCID-Profile: Rositsa Mihaylova, Ivo D Ivanov, Zhanina Petkova, Georgi Momekov, Denitsa Momekova, Anife Ahmedova
Förderung
- National Science Fund of Bulgaria
Zitieren
APA
Mihaylova, R., Mihaylova, V., Burdzhiev, N., Ivanov, I. D., Petkova, Z., Momekov, G., Momekova, D., & Ahmedova, A. (2026). Asymmetrically Disubstituted Pyrenebutyrate Complexes of Pt(IV) as Cisplatin Prodrugs with Improved Anticancer Activity. Molecules, 31(13), 2336. https://doi.org/10.3390/molecules31132336
Vancouver
Mihaylova R, Mihaylova V, Burdzhiev N, Ivanov ID, Petkova Z, Momekov G, et al. Asymmetrically Disubstituted Pyrenebutyrate Complexes of Pt(IV) as Cisplatin Prodrugs with Improved Anticancer Activity. Molecules. 2026;31(13):2336. doi:10.3390/molecules31132336
BibTeX
@article{Mihaylova2026,
author = {Mihaylova, Rositsa and Mihaylova, Veronika and Burdzhiev, Nikola and Ivanov, Ivo D and Petkova, Zhanina and Momekov, Georgi and Momekova, Denitsa and Ahmedova, Anife},
title = {Asymmetrically Disubstituted Pyrenebutyrate Complexes of Pt(IV) as Cisplatin Prodrugs with Improved Anticancer Activity},
journal = {Molecules},
year = {2026},
volume = {31},
number = {13},
pages = {2336},
doi = {10.3390/molecules31132336}
}
EUVIMED